How to Increase U.S. Fertility Rates

Close to $50,000: the average family spends roughly $50k and more than two rounds of IVF to conceive, while U.S. IVF births are 2.6% versus Denmark's ~10%, underlining affordability and access gaps. The author urges policy moves — mandated coverage (egg freezing, IUI, donation, male testing), GLP‑1 metabolic care coverage for fertility (60% of GLP‑1 users are women), and AI-enabled integrated prenatal/postpartum platforms — as pragmatic levers to raise birth rates and improve maternal outcomes.

Analysis

Policy momentum plus consumer health tech creates a classic demand-pull with supply-side chokepoints: employer-funded benefits and reimbursed prescriptions would re-price who pays for family-building care and rapidly shift spend off direct out-of-pocket channels into insured/managed channels over 12–36 months. That flow disproportionately favors scaled service aggregators (benefits managers, national clinic networks) and large-cap pharma with manufacturing depth, while creating durable margin upside for vendors of high-throughput lab equipment and specialty disposables.

If GLP-1 indications or formal coverage narratives expand to include metabolic–reproductive endpoints, expect a two-stage market reaction: an initial rerating of incumbent peptide players on visible TAM expansion, followed by a second leg driven by supply constraints — API, sterile fill/finish, and distribution logistics have typical lead times of 6–12 months and will bottleneck unit economics in the near term. This structural bottleneck creates optionality for manufacturers who can scale production quickly and for contract manufacturers that win incremental capacity contracts.

AI-enabled continuity-of-care platforms are the cheapest lever to reduce per-patient downstream costs that payers care about; vendors that can show measurable reductions in ER visits, preterm births, or postpartum readmissions will extract PMPM fees and become acquisition targets for larger telehealth incumbents within 12–24 months. Expect consolidation where telehealth winners bolt-on niche fertility/maternity assets to offer end-to-end funnels that lock employers into holistic benefits packages.

Key reversal risks are regulatory pushback on off-label prescribing, high-profile adverse events or shortages that force rationing, and the multiyear lag between coverage change and demonstrable population-level fertility outcomes. Near-term share moves will be driven by policy signals and capacity announcements; durable birth-rate improvements, however, remain a multi-year arbitrage and should be sized accordingly.

Key Decisions for Investors

• Long PGNY (Progyny) — 12–24 month horizon. Rationale: direct exposure to employer-funded fertility spend and benefit-management take-up; position size: 2–4% net exposure. Risk/Reward: asymmetric upside (30–60% if adoption and mandates accelerate) vs limited downside (20–30%) if reimbursement cycles slow.
• Long LLY (Eli Lilly) — 6–18 month horizon via out-of-the-money 12-month calls to capture label/coverage expansion for GLP-1s. Rationale: scale manufacturing and pricing power; hedge with modest position in NVO if concerned about single-company execution risk. Risk/Reward: high upside if indications/coverage expand quickly; downside if pricing controls or supply limits compress volumes.
• Long COO (CooperCompanies) or TMO (Thermo Fisher) — 12–36 month horizon. Rationale: exposure to durable demand for fertility lab consumables and equipment as utilization moves onshore and scales. Risk/Reward: steady mid-single-digit organic growth plus margin expansion if utilization increases; downside from competitive pricing or capital spending slowdowns.
• Pair trade: Long TDOC (Teladoc) / Short WW (WW International) — 6–12 month horizon. Rationale: favor integrated telehealth/AI monitoring vendors that capture PMPM fees over pure-play consumer weight-loss names exposed to GLP-1 commoditization. Risk/Reward: capture re-rating of care-coordination models with limited downside if telehealth adoption stalls; short is hedge against DTC demand loss.